ABSTRACT
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INTRODUCTION
During normal pregnancy, significant changes occur to the maternal cardiovascular system. These adaptations include changes in maternal arterial stiffness to allow for normal fetal development 1 . Arterial stiffness and peripheral vascular resistance drop during early pregnancy, stimulating an increase in plasma volume, vital for adequate placental circulation and therefore fetal growth [2] [3] [4] [5] . In certain populations of pregnant women, these normal changes in arterial stiffness do not occur as expected, which may be because of complex maladaptation or underlying endothelial dysfunction 6 . In mothers with pregestational or gestational diabetes, increased arterial stiffness (stiffer arteries) has been reported 6 . Increased arterial stiffness in adults is associated with adverse cardiovascular events, including myocardial infarction and stroke 7, 8 . During pregnancy, increased arterial stiffness has also been implicated in adverse outcomes for both the mother and the fetus, with links to pre-eclampsia and fetal growth restriction (FGR) [9] [10] [11] [12] . The mechanism of fetal compromise in these cases relates to placental function. Placental function and fetal cardiovascular function are directly related, as fetoplacental function reflects cardiac afterload 13 . Although the effects of increased maternal arterial stiffness on fetoplacental function have been demonstrated indirectly, the impact of maternal arterial stiffness on fetal cardiovascular physiology has not been studied extensively.
The arterial augmentation index (AIx) measured non-invasively by applanation tonometry is a surrogate marker of arterial stiffness and is a safe, easy and reproducible means of determining vascular health 14, 15 . In this study, using this modality, we sought to determine if maternal arterial stiffness in diabetic pregnancies is associated with the parameters used to measure placental and fetal cardiovascular physiology, in particular prior to the development of, or in the absence of, FGR secondary to placental insufficiency. We hypothesized that, in pregnant women with gestational or pregestational diabetes, placental and fetal cardiovascular physiology would be altered secondary to increased maternal arterial stiffness, manifesting as abnormal echocardiographic measures of cardiovascular function in the fetus.
METHODS
Patients
A prospective study was conducted at Lucile Packard Children's Hospital, Palo Alto, CA, USA between December 2013 and January 2017. Participants in the study were pregnant women referred to the Heart Center by their obstetricians for fetal echocardiography owing to risk factors or concerns for fetal congenital heart disease, in keeping with indications established in recent guidelines for the diagnosis and treatment of fetal cardiac disease 16 . With regard to maternal diabetes, current recommendations for fetal echocardiography screening include those with pregestational diabetes, those with gestational diabetes diagnosed during the first trimester of pregnancy and those with poorly controlled diabetes through the course of pregnancy 16 . Inclusion criteria for the study were women between the ages of 18 and 40 years with a singleton pregnancy at 20-28 weeks' gestation, as maternal AIx has been shown to be least variable during this period 3 ; normal fetal cardiac structures, including normal thickness of the interventricular septum on the fetal echocardiogram performed at the initial visit; and referral for gestational or pregestational diabetic pregnancy. Exclusion criteria were in-vitro fertilization pregnancy, maternal history of congenital heart disease, given the reported potentially abnormal uteroplacental blood flow in these patients 17 ,
conditions that could affect arterial stiffness such as maternal antibody mediated rheumatological disease including systemic lupus erythematosus and Sjogren's syndrome, known fetal extracardiac or chromosomal abnormalities, fetal hydrops, FGR, maternal food intake within 3 h prior to testing owing to its effects on AIx 18, 19 , gestational hypertension and pre-eclampsia.
The study protocol was approved by the Stanford University Institutional Review Board, Protocol #29033, and informed consent was obtained from all subjects.
Clinical data
Data collection for the mother included a brief questionnaire prior to study testing and review of patient medical records to obtain information regarding maternal cardiovascular health and risk factors. The information gathered consisted of prepregnancy medical history including history of diabetes, hypertension, smoking, alcohol use, prepregnancy weight, pregnancy history including gestational diabetes or hypertension, glycated hemoglobin (HbA1c) level, family history of diabetes, hypertension, high cholesterol, coronary artery disease, stroke, Raynaud's disease and rheumatologic disease and dietary history including intake of medications, coffee, tea, soft drinks or alcohol in the 24 h prior to testing. Gestational diabetes was defined as an abnormal glucose tolerance test during pregnancy and pregestational diabetes was based on documentation in previous medical records and abnormal glucose testing prepregnancy.
Testing
The tonometry protocol was conducted after the routine fetal echocardiogram was complete. Measurements of height and weight were obtained (Scaletronix scale, White Plains, NY, USA; Seca stadiometer, Columbia, MD, USA). Blood pressure was measured on the testing arm in a sitting position using the oscillometric method (Dinamap-GE, Waukesha, WI, USA) after at least 5 min of rest. The average of the last three BP measurements was used. Arterial applanation tonometry was performed to obtain AIx in the mother (Sphygmocor CPV, Atcor Medical, Sydney, Australia). The room lights were dimmed and the mother was asked to lie in the supine position. The tonometer was applied to the right radial arterial pulse, and 10 pulse waveforms were auto-captured. Measurements were kept if they met the quality criteria established by the manufacturer. The central aortic pulse pressure waveform was generated from a generalized transfer function that has been validated in adults using invasive catheterization data 20, 21 . AIx was calculated as the ratio (%) of the pressure augmentation caused by the reflected wave and the pulse pressure, represented by the formula: AIx = (augmentation pressure/pulse pressure) × 100, where augmentation pressure is the difference between the first and second peaks in the central arterial waveform. Given the linear relationship between heart rate and AIx, and the anticipated rise in heart rate during pregnancy, we used AIx at 75 bpm (AIx 75 ) in all subjects 22 . Information regarding fetal cardiovascular physiology was obtained from the images routinely acquired for a complete fetal echocardiogram in our laboratory. Spectral Doppler-derived resistance indices (RI) of the umbilical artery (UA) and middle cerebral artery (MCA) were assessed as measures of uteroplacental sufficiency and fetal wellbeing. Left (LV) and right (RV) ventricular end-diastolic and systolic measurements and fractional area change were calculated. The velocity time integral (VTI), an integration of flow velocities in a given period of time, yielding a distance from a continuous wave Doppler velocity profile of the pulmonary and aortic (AoV) valves was recorded 23 , and combined cardiac output (derived from AoV and pulmonary valve annulus size and respective VTI measurements as well as heart rate) was calculated. LV myocardial performance index (MPI), defined as the sum of isovolumic contraction and relaxation times divided by ejection time using simultaneous LV inflow and outflow pulsed-wave Doppler, was measured. Myocardial tissue Doppler e velocity at the tricuspid valve annulus, Doppler patterns in the umbilical vein and ductus venosus, the presence of atrioventricular valve regurgitation or pericardial effusion and fetal weight estimated by the Hadlock equation were documented 24 . Echocardiography was performed using Philips ultrasound machines (Philips iE33 Ultrasound System, Andover, MA, USA).
Inter-and intraobserver reproducibility was tested for both arterial applanation tonometry and echocardiographic measurements, with a second observer performing tonometry on 10 subjects and echocardiographic measurements in five studies.
Statistical analysis
Descriptive statistics were calculated, with continuous data presented as mean ± SD or median (range). Comparisons were made between all diabetic women and controls, among groups of patients with pregestational diabetes and gestational diabetes and between obese diabetic patients and controls. Comparisons were also made between patients based on HbA1c levels. Parametric testing was used to compare data with a normal distribution and non-parametric testing was used to compare data with a non-normal distribution. All comparisons were performed using Student's t-test, the Mann-Whitney U-test or Fisher's exact test. Pearson's correlation coefficient was used to assess for a correlation between maternal arterial stiffness and fetal cardiovascular parameters. This study was powered at 90% to detect a difference of 0.1 in RI based on prior studies 25 .
RESULTS
Patients
Eighty patients met the inclusion criteria and were approached for participation in the study. Fourteen of these patients were subsequently excluded because of the exclusion criteria. Twenty-three healthy pregnant women (controls) and 43 pregnant women with diabetes (22 with pregestational diabetes and 21 with gestational diabetes) were included in the study. Controls were women referred for a family history of congenital heart disease, teratogen exposure, difficulty viewing all structures of the fetal heart, suspicion of abnormal fetal cardiac structures on screening ultrasound, increased nuchal translucency thickness or a finding of an echogenic focus, all with normal fetal echocardiograms on assessment.
Sixteen of the pregestational diabetic women were taking insulin, four metformin and two glyburide. In the gestational diabetes group, four participants were taking insulin and two were taking glyburide. In the rest of the women with gestational diabetes the diabetes was controlled by diet. Demographic data were similar between diabetic women and controls (Table 1) apart from blood pressure (hypertension in 1/43 diabetics) and prepregnancy weight (obesity, defined as body mass index > 30 kg/m 2 , in 23/43 diabetics), as anticipated. Maternal age, which can potentially have an effect on both maternal vascular health and fetal outcome, was not different between the groups. Fetal gestational ages and weights were similar (Table 1 ). No differences in the above variables were observed when patients with pregestational and gestational diabetes were compared.
Arterial stiffness
AIx 75 was higher in diabetic patients than in controls (12.4 ± 10.6% vs 4.6 ± 7.9%; P = 0.003) (Figure 1 ). On subgroup analysis, both pregestational and gestational diabetes patients had higher AIx 75 than did controls (12.6 ± 10.1% in patients with pregestational diabetes (P = 0.006) and 12.2 ± 11.3% in patients with gestational diabetes (P = 0.014)).
Fetal cardiovascular indices
MCA-RI and UA-RI were similar between diabetic women and controls. Doppler patterns in the umbilical vein and ductus venosus were normal in all participants. No significant atrioventricular valve regurgitation or pericardial effusion was noted in either group. Tissue Doppler-derived e velocity at the tricuspid valve annulus, and LV and RV fractional area changes, stroke volumes and outputs, as well as fetal heart rate, were similar between groups. Combined cardiac output indexed to estimated fetal weight was also similar between groups (516.8 ± 131.5 mL/kg/min in diabetics vs 490.4 ± 131.9 mL/kg/min in controls; P = 0.44) ( Table 2 ). VTI across the AoV was significantly different between diabetic women and controls, with higher VTI in diabetic women than in controls (7.7 ± 1.9 cm in diabetics vs 6.3 ± 3.0 cm in controls; P = 0.022) (Figure 2) . LV-MPI was also found to be significantly different between diabetic women and controls, with lower LV-MPI values in diabetic women (0.40 ± 0.09 vs 0.46 ± 0.11; P = 0.021) (Figure 3 ).
Glucose control
Twenty-four diabetic patients had normal (< 6.5%) HbA1c levels and 17 diabetic patients had HbA1c levels ≥ 6.5%, with eight of these above 7.5% and four of those above 8.5%. HbA1c levels were not available for two participants. When we analyzed the diabetic patients (pregestational and gestational diabetes) based on their HbA1c level (≥ 6.5% vs < 6.5%), we found that patients with HbA1c ≥ 6.5% had significantly lower UA-RI values (HbA1c ≥ 6.5%: 0.69 ± 0.06, n = 15 vs HbA1c < 6.5%: 0.76 ± 0.08, n = 21; P = 0.009) (Figure 4 ). This finding did not hold true when using an HbA1c level of 7.5% or 8.5% as a cut-off.
Arterial stiffness and placental and fetal cardiovascular physiologic indices
When stratified by degree of stiffness, significant differences were found in AoV-VTI; it was 7.8 ± 2.5 cm for those with AIx 75 > 10% vs 6.6 ± 2.3 cm for those with AIx 75 < 10% (P = 0.043) and 8.4 ± 2.6 cm for those with AIx 75 > 15% vs 6.8 ± 2. (r 2 = 0.0002, P = 0.913) or UA-RI and AIx 75 (r 2 = 0.039, P = 0.139) ( Figure 5 ).
Interobserver variability
The intraclass correlation coefficients for AoV-VTI and LV-MPI measurements were excellent at 0.97 (CI 95%, 
DISCUSSION
Diabetes, both pregestational and gestational, is a well-established cardiovascular risk factor for pregnant women [26] [27] [28] . An underlying mechanism for adverse cardiovascular outcomes in such women may be related to abnormal arterial stiffness. Diabetic pregnancies also have serious consequences for the fetus, including congenital malformations, abnormal fetal growth, prematurity, complications secondary to hypoxia, birth trauma and an increased risk of mortality 29 . As the incidence of diabetes during pregnancy continues to increase, understanding the impact on the developing fetus is important, especially given the possibility of fetal origin of adult disease, resulting in long-term cardiovascular consequences for the fetus.
In our study, similarly to previous studies, we have demonstrated stiffer arteries in gestational and pregestational diabetic mothers than in controls 6, 30 . We have also demonstrated that fetal cardiovascular physiology is altered in diabetic pregnancies. Interestingly, no correlation was found between these maternal and fetal findings.
Fetuses of diabetic mothers had significantly higher AoV-VTI; AoV-VTI multiplied by aortic annulus size yields LV stroke volume. Given that AoV-VTI was altered, one would expect LV stroke volume to be different between the groups. If stroke volume was altered, this may support a hypothesis of unequal distribution of flow between the right and left heart, related to placental resistance. However this was not noted in the study, there being no significant difference in AoV annulus size, stroke volume, heart rate or combined cardiac output indexed to estimated fetal weight. It is possible that our study was underpowered to detect a difference in output, despite the difference in VTI, and this warrants future assessment, especially given that increased fetal cardiac output in diabetic pregnancies has been observed previously 31 . Interestingly, previous studies have shown changes in cardiovascular function, including VTI, in fetuses with FGR, a finding associated with increased maternal arterial stiffness 32 . All the fetuses in our study had normal weight. It would be interesting to see if any fetuses went on to develop growth restriction and to assess whether changes in VTI persist through pregnancy or beyond into postnatal life.
LV-MPI was also significantly different between the groups, with lower values in diabetic pregnancies. MPI is a marker of global cardiac function, used as an early indicator of myocardial dysfunction in the fetus in numerous pathologic states, with higher values representing dysfunction. Previous studies assessing this parameter in diabetic pregnancies have found varying results; unchanged, increased or decreased MPI [33] [34] [35] [36] [37] . Other markers of myocardial function, such as long-axis function in diabetic pregnancy, have also been studied, showing decreased function with higher maternal HbA1c levels 38 . Lower MPI values in diabetic pregnancies are not entirely intuitive, as this would imply better function. This finding may be related to the fact that none of the fetuses in our study was large-for-gestational age and none had myocardial hypertrophy, factors associated with impaired function. That being said, hypertrophic cardiomyopathy in fetuses of diabetic mothers has also been associated with improved myocardial long-axis function over the course of gestation, as a sign of adaptation 39 . Perhaps lower MPI, in addition to increased VTI, represents a hyperdynamic state in response to abnormal glucose metabolism. Interestingly, in the animal model, improvement in cardiac function during fetal tachycardia has been demonstrated during maternal hyperglycemia and induced fetal hyperinsulinemia 40, 41 . It may be speculated that a similar metabolic state in the human fetus could induce increased myocardial function even at normal heart rates. Further studies would be required to assess this.
Advanced imaging techniques such as tissue Doppler and strain imaging are useful tools in assessing fetal myocardial function, used as an early marker of abnormal cardiac physiology 39, 42 . Although abnormal tissue Doppler values in diabetic pregnancies have been described previously, similar to our findings, other studies have found no significant differences 43, 44 . This may be owing to our cohort's having no evidence of myocardial hypertrophy. Strain imaging was not performed in this study, however, previous assessment of myocardial deformation in diabetic pregnancies has shown significant findings 45 . The association between myocardial deformation and AIx would be interesting to assess in future studies.
Placental function was found to be normal in all subjects, offering no etiologic link between maternal AIx and fetal cardiovascular findings 25 . Although the exact role for screening HbA1c levels during pregnancy has not yet been formally established, it is generally accepted that women with a HbA1c level of <6-6.5% should be targeted 46 . When diabetes was stratified by glucose control, patients with HbA1c ≥ 6.5% had significantly lower UA-RI than did patients with lower levels of HbA1c. Although the difference was significant, all values still fell within the normal reference range 47 . Therefore, it is unlikely that this difference represents a pathological condition, especially since this finding did not hold true at higher HbA1c cut-offs, and given that it is in contrast to previous studies that reported either no difference or higher UA-RI in pregnancies with higher HbA1c levels [48] [49] [50] [51] . Alternatively, the finding may be a fetal compensatory response to relative placental insufficiency. As documented previously, uteroplacental blood flow is reduced in diabetic pregnancies 52 . Hyperglycemia may affect the uptake of nitric oxide, influencing the autocrine regulation of placental perfusion 53 . In the fetal sheep model of maternal hyperglycemia, the distribution of blood flow is altered, with increased flow to the vital organs such as the brain, heart and kidneys and reduced placental flow 54 . This may necessitate reduced resistance to flow in the placenta to allow for improved flow in the fetoplacental circulation.
This study has some limitations. The sample size was small; a larger study may detect more pronounced differences. The study was not powered to comment on the impact of obesity or hypertension; however, subanalysis with stratification of the groups based on these variables may provide further insight into the pathophysiology found in these patients. Patients were not followed to delivery; further testing through the course of pregnancy and into postnatal life may provide a better understanding of the significance of the mid-gestation findings. Advanced imaging techniques such as strain imaging may provide useful information about myocardial function and should be explored further.
In conclusion, arterial stiffness, as measured by AIx, is increased in pregnant women with diabetes. Fetal cardiovascular physiology is altered in diabetic pregnancies, with higher AoV-VTI and lower LV-MPI than in controls. No correlation between these values was found, with placental function being normal. These findings probably represent fetal adaptation to abnormal hemodynamics in these pregnancies, with both a maternal and a fetal response to a milieu of altered glucose metabolism. The clinical implications of such changes remain unclear; however, they do raise an important question regarding the significance of optimal glucose control during pregnancy and the potential for cardiovascular consequences for the developing fetus.
